These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29394033)

  • 1. Metallointercalators and Metalloinsertors: Structural Requirements for DNA Recognition and Anticancer Activity.
    Schatzschneider U
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-covalent Metallo-Drugs: Using Shape to Target DNA and RNA Junctions and Other Nucleic Acid Structures.
    Cardo L; Hannon MJ
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleic Acid Quadruplexes and Metallo-Drugs.
    Vilar R
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Metallodrugs that Target Proteins.
    Sullivan MP; Holtkamp HU; Hartinger CG
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
    Babak MV; Ang WH
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal Chemistry of Gold Anticancer Metallodrugs.
    Casini A; Sun RW; Ott I
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polynuclear Platinum Complexes. Structural Diversity and DNA Binding.
    Brabec V; Kasparkova J; Menon V; Farrell NP
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group 9 organometallic compounds for therapeutic and bioanalytical applications.
    Ma DL; Chan DS; Leung CH
    Acc Chem Res; 2014 Dec; 47(12):3614-31. PubMed ID: 25369127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency.
    Komor AC; Barton JK
    J Am Chem Soc; 2014 Oct; 136(40):14160-72. PubMed ID: 25254630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of metal ions with DNA, its constituents and derivatives, which may be relevant for anticancer research.
    Turel I; Kljun J
    Curr Top Med Chem; 2011; 11(21):2661-87. PubMed ID: 22039873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging.
    Karaca Ö; Meier-Menches SM; Casini A; Kühn FE
    Chem Commun (Camb); 2017 Jul; 53(59):8249-8260. PubMed ID: 28653066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics.
    Hartinger CG; Phillips AD; Nazarov AA
    Curr Top Med Chem; 2011; 11(21):2688-702. PubMed ID: 22039871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordination Complexes of Titanium(IV) for Anticancer Therapy.
    Tshuva EY; Miller M
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonochemical synthesis, DNA binding, antimicrobial evaluation and in vitro anticancer activity of three new nano-sized Cu(II), Co(II) and Ni(II) chelates based on tri-dentate NOO imine ligands as precursors for metal oxides.
    Abdel-Rahman LH; Abu-Dief AM; El-Khatib RM; Abdel-Fatah SM
    J Photochem Photobiol B; 2016 Sep; 162():298-308. PubMed ID: 27395793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
    Alessio E; Messori L
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro.
    Kamatchi TS; Chitrapriya N; Lee H; Fronczek CF; Fronczek FR; Natarajan K
    Dalton Trans; 2012 Feb; 41(7):2066-77. PubMed ID: 22183160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition metal based anticancer drugs.
    Garbutcheon-Singh KB; Grant MP; Harper BW; Krause-Heuer AM; Manohar M; Orkey N; Aldrich-Wright JR
    Curr Top Med Chem; 2011; 11(5):521-42. PubMed ID: 21189131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrophosphate-bridged complexes with picomolar toxicity.
    Ikotun OF; Higbee EM; Ouellette W; Doyle RP
    J Inorg Biochem; 2009 Sep; 103(9):1254-64. PubMed ID: 19666193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.
    Boyle KM; Barton JK
    J Am Chem Soc; 2018 Apr; 140(16):5612-5624. PubMed ID: 29620877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.